Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Usp Fiziol Nauk ; 47(4): 18-42, 2016.
Artigo em Russo | MEDLINE | ID: mdl-29283233

RESUMO

Kirov State Medical Academy, Kirov The results of the 20-years studies of the presence in blood serum and other body fluids of endogenous modulators of adrenergic and M-cholinergic impact a A COMPONENT of humoral element of autonomic nervous system. The article is devoted to the endogenous sensitizer of beta-adrenergic receptor (ESBAR) - water-soluble low molecular weight substances, analogues of which are histidine, tryptophan, tyrosine, mildronat and preduktal. It is shown, that separate dilutions of human serum and animal (as a source of ESBAR) and ESBAR - analogues ways to enhance the effectiveness of activation of beta-adrenoceptors (AR) of smooth muscle (uterus, coronary and renal arteries, trachea, stomach), myocardium and erythrocytes and platelets (respectively influenced of histidine and tryptophan). It is reported? that content of ESBAR in human serum (according to the titers of its dilution) depends on the sex and the presence of somatic diseases, and at women are also on the stage of reproduction and obstetric complications It is discussed hossible mechanisms of ESBAR action, its physiological role, including as a component of beta-adrenoreceptor myometrium inhibitory mechanism, as well as the prospect of the use of analogues ESBAR, including for the prevention of preterm labor, and for the treatment of bronchial asthma, coronary heart disease, hypertension and heart failure.


Assuntos
Agonistas Adrenérgicos/uso terapêutico , Sistema Nervoso Autônomo/efeitos dos fármacos , Agonistas Colinérgicos/uso terapêutico , Insuficiência Cardíaca/prevenção & controle , Músculo Liso/efeitos dos fármacos , Trabalho de Parto Prematuro/prevenção & controle , Agonistas Adrenérgicos/sangue , Asma/tratamento farmacológico , Asma/metabolismo , Asma/fisiopatologia , Sistema Nervoso Autônomo/metabolismo , Sistema Nervoso Autônomo/fisiopatologia , Agonistas Colinérgicos/sangue , Doença das Coronárias/tratamento farmacológico , Doença das Coronárias/metabolismo , Doença das Coronárias/fisiopatologia , Feminino , Insuficiência Cardíaca/metabolismo , Insuficiência Cardíaca/fisiopatologia , Histidina/sangue , Histidina/uso terapêutico , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/metabolismo , Hipertensão/fisiopatologia , Metilidrazinas/uso terapêutico , Músculo Liso/metabolismo , Músculo Liso/fisiopatologia , Trabalho de Parto Prematuro/metabolismo , Trabalho de Parto Prematuro/fisiopatologia , Gravidez , Triptofano/sangue , Triptofano/uso terapêutico , Tirosina/sangue , Tirosina/uso terapêutico
2.
Bioorg Med Chem ; 23(13): 3831-42, 2015 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-25900628

RESUMO

Replacing hydrogen with deuterium as a means of altering ADME properties of drug molecules has recently enjoyed a renaissance, such that at least two deuterated chemical entities are currently in clinical development. Although most research in this area aims to increase the metabolic stability, and hence half-life of the active species, experience has shown that prediction of the in vivo behaviour of deuterated molecules is difficult and depends on multiple factors including the complexity of the metabolic scheme, the enzymes involved and hence the mechanism of the rate-determining step in the biotransformation. In an effort to elucidate some of these factors we examined the metabolic behaviour of two molecules from the Sanofi portfolio in a range of in vitro and in vivo systems. Although some key metabolic reactions of the acetylcholine release stimulator HP184 4 were slowed in vitro and in vivo when deuterium was present at the sites of metabolism, this did not translate to an increase in overall metabolic stability. By contrast, the tryptase inhibitor AVE5638 13 was much more metabolically stable in vitro in its deuterated form than when unlabelled. These results indicate that it could be of value to concentrate efforts in this area to molecules which are metabolised by a major pathway that involves enzymes of the amine oxidase family or other low-capacity enzyme families.


Assuntos
Agonistas Colinérgicos/sangue , Hepatócitos/metabolismo , Indóis/sangue , Piridinas/sangue , Inibidores da Tripsina/sangue , Animais , Biotransformação , Linhagem Celular , Agonistas Colinérgicos/farmacocinética , Deutério , Estabilidade de Medicamentos , Hepatócitos/citologia , Hepatócitos/efeitos dos fármacos , Humanos , Hidrogênio , Indóis/farmacocinética , Masculino , Monoaminoxidase/metabolismo , Piridinas/farmacocinética , Ratos , Ratos Sprague-Dawley , Inibidores da Tripsina/farmacocinética
3.
Xenobiotica ; 44(6): 531-40, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24479584

RESUMO

1. Metabolism and disposition of ABT-894 was investigated in hepatocytes, in mice and monkeys receiving [(14)C]ABT-894. 2. In hepatocytes, turnover rate of ABT-894 was slow in all species with more than 90% of parent remaining. M3 (carbamoyl glucuronide) and M6 (mono-oxidation) were detected across species. 3. ABT-894 showed species-specific disposition profiles. ABT-894 was primarily eliminated by renal secretion in mice. Whereas, monkey mainly cleared ABT-894 metabolically. 4. ABT-894 underwent two primary routes of metabolism in monkeys: N-carbamoyl glucuronidation to form M3 and oxidation product M1. M3 was the major metabolite in monkey excreta. M3 was observed in mice urine. Circulating levels of M3 in terms of M3/ABT-894 ratios were essentially absent in mice, but were high in monkeys. 5. Understanding the species difference in the clearance mechanism is the key to the accurate projection of the human clearance and preclinical safety assessment. Lack of species difference in the metabolism of ABT-894 in hepatocytes certainly creates a challenge in predicting its metabolism and pharmacokinetics in human. Based on available metabolism and pharmacokinetic data of ABT-894 in human, monkey is the preferred species in predicting human clearance since it presents a similar clearance mechanism from that observed in human.


Assuntos
Compostos Azabicíclicos/metabolismo , Compostos Azabicíclicos/farmacocinética , Compostos Bicíclicos com Pontes/metabolismo , Compostos Bicíclicos com Pontes/farmacocinética , Agonistas Colinérgicos/metabolismo , Agonistas Colinérgicos/farmacocinética , Neurônios/metabolismo , Piridinas/metabolismo , Piridinas/farmacocinética , Receptores Nicotínicos/metabolismo , Animais , Compostos Azabicíclicos/sangue , Compostos Azabicíclicos/química , Compostos Bicíclicos com Pontes/sangue , Compostos Bicíclicos com Pontes/química , Agonistas Colinérgicos/sangue , Agonistas Colinérgicos/química , Cromatografia Líquida de Alta Pressão , Cães , Absorção Gastrointestinal , Haplorrinos , Hepatócitos/metabolismo , Humanos , Masculino , Espectrometria de Massas , Redes e Vias Metabólicas , Camundongos , Piridinas/sangue , Piridinas/química , Ratos Sprague-Dawley , Receptores Nicotínicos/química , Distribuição Tecidual
4.
Acta bioquím. clín. latinoam ; 46(4): 656-659, dic. 2012. graf, tab
Artigo em Espanhol | LILACS | ID: lil-671973

RESUMO

La agregación por transmisión de luz (ATL) es el método más usado por laboratorios clínicos y de investigación para evaluar la función plaquetaria y es considerado actualmente el estándar de oro; no obstante, la ATL aún no es un método estandarizado, pese a los esfuerzos de organismos internacionales como la International Society of Thrombosis and Hemostasis (ISTH). Organismos regulatorios recomiendan que cada laboratorio clínico determine e informe sus intervalos de referencia (IR) para cada agonista que utiliza. Se presenta los IR de este laboratorio en la determinación de agregación plaquetaria mediante ALT utilizando adenosin difosfato (ADP), colágeno y adrenalina como agonistas. Para ello se diseñó un estudio de corte transversal sobre una muestra a conveniencia de voluntarios(as) aparentemente sanos; se usó un agregómetro óptico y se emplearon los siguientes agonistas y concentraciones finales: ADP 5 µM, colágeno 2 µM y adrenalina 10 µM. Se definió IR como los percentiles 2,5 y 97,5 (P2,5 y P97,5) del Porcentaje de Agregación Plaquetaria Máxima APM%. Participaron 63 individuos, rango de edad 18 a 66 años, 79,4% sexo femenino. Los valores de APM% fueron: ADP P2,5=49% y P97,5=87%; colágeno P2,5=43% y P97,5=86%; adrenalina P2,5=42% y P97,5=85%. Atendiendo a recomendaciones internacionalmente aceptadas, se presentan los IR de APM (%) por el método ATL en este laboratorio (ASCARDIO, Barquisimeto, Venezuela), lo que permite al clínico basar sus decisiones en evidencia válida y pertinente.


Platelet aggregation tests by means of light transmission (LTA), the current gold standard, are the most commonly used methods used to evaluate platelet function at clinical and research laboratories. However, LTA has not been determinastandardized despite the work from international organizations such as the International Society of Thrombosis and Homeostasis (ISTH). Regulatory agencies recommend that each clinical laboratory establishes and informs its own Reference Internal (RI) for all agonists they use. RI are presented for our laboratory using the following agonists: diphosphate (ADP), collagen y adrenaline and the pertaining methodology. To assess our RI for platelet aggregation tests by LTA, a cross-sectional study was designed with a convenience sample of healthy volunteer men and women using an optical aggregometer with the following agonist and final concentration: adenosine diphosphate (ADP) 5 µM, collagen 2 µM and adrenaline 10 µM. The RIs were defined as Percentiles 2.5 (P2,5) and 97.5 (P97.5) of the percentage of maximal aggregation (%MA). 63 subjects participate, age range 18 to 66,79.4% were female. The IR for %MA were: ADP P2,5=49% and P97.5=87%; collagen P2,5=43% and P97.5=86%; adrenaline P2,5=42% and P97.5=85%. In agreement with international accepted recommendation guidelines, RIs for the %MA values were presented by LTA done in our clinical laboratory (ASCARDIO, Barquisimeto, Lara State, Venezuela), that allows physicians to base their clinical decision process on valid and pertinent information.


A agregometria por transmissão de luz (ATL) é o método mais utilizado pelos laboratórios clínicos e de pesquisa para avaliar a função plaquetária e é atualmente considerada o padrão-ouro; no entanto, a ATL ainda não é um método padronizado, apesar dos esforços das agências internacionais como a International Society of Thrombosis and Hemostasis (ISTH). Agências reguladoras recomendam que cada laboratório clínico determine e comunique seus intervalos de referência (IR) para cada agonista utilizado. São apresentados o IR de nosso laboratório para determinar a agregação plaquetária através de ALT usando Difosfato de Adenosina (ADP), Colágeno e Adrenalina como agonistas. Para isso foi elaborado um estudo de corte transversal em uma amostra de conveniência de voluntários(as) aparentemente saudáveis , foi usado agregômetro ótico e foram utilizados os seguintes agonistas e concentrações finais: 5µ M ADP, Colágeno 2µM e Adrenalina 10µM. Definiu-se o IR com os percentis 2,5 e 97.5 (P2,5 e P97.5) do Percentual de Agregação Plaquetária Máxima APM%. Participaram 63 indivíduos, na faixa etária 18-66 anos, 79,4% do sexo feminino. Os valores de APM% foram: ADPP2,5=49% e P97.5=87%; Colágeno P2,5=43% e P99,5=86%, Adrenalina P2,5=42% e P97.5=85%. Atendendo às recomendações aceitas internacionalmente, apresentam-se os IR de APM% pelo método ATL em nosso laboratório (ASCARDIO, Barquisimeto, Venezuela), o que permite ao médico basear as suas decisões em evidências válidas e pertinentes.


Assuntos
Humanos , Masculino , Feminino , Agregação Plaquetária/fisiologia , Difosfato de Adenosina/agonistas , Agonistas Colinérgicos/sangue , Transtornos Hemorrágicos/diagnóstico , Valores de Referência
5.
J Pharm Biomed Anal ; 14(1-2): 131-42, 1995 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8833975

RESUMO

A high-performance liquid chromatographic method with fluorescence detection was developed for a series of cholinergic channel activators using 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-F) as a fluorescent labeling reagent. This method includes three separate steps: extraction of parent compound and internal standard with organic solvent from plasma, reaction of parent and internal standard in NBD-F precolumn to yield a fluorescent product and extraction of the resultant fluorophores with organic solvents. The extraction and reaction procedures were optimized for this series of structurally new compounds. The method showed high sensitivity, selectivity and reproducibility and proved useful for the determination of ng ml-1 plasma levels of selected cholinergic channel activators.


Assuntos
4-Cloro-7-nitrobenzofurazano/análogos & derivados , Agonistas Colinérgicos/análise , Corantes Fluorescentes/química , Pirrolidinas/análise , 4-Cloro-7-nitrobenzofurazano/química , Animais , Agonistas Colinérgicos/sangue , Agonistas Colinérgicos/farmacocinética , Cromatografia Líquida de Alta Pressão , Remoção de Radical Alquila , Cães , Haplorrinos , Concentração de Íons de Hidrogênio , Indicadores e Reagentes , Espectrometria de Massas , Pirrolidinas/sangue , Pirrolidinas/farmacocinética , Padrões de Referência , Solventes , Espectrofotometria Ultravioleta , Temperatura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...